Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal seizures, with temporal lobe onset with or without secondary generalization. Up to 70 subjects will be enrolled. Eligible subjects will be randomized in a 1:1 ratio to either CT-010 or placebo treatment. Up to 20 clinical centers will be enrolled.


Clinical Trial Description

Epilepsy patients that are refractory to oral anti-epileptic drug (AED) treatment have significantly higher mortality, higher morbidity, higher economic costs and diminished quality of life compared to those who suffer from epilepsy that can be adequately controlled with medical management. Current options for refractory patients include neurosurgical brain resection, responsive neurostimulation, and vagal nerve stimulation. None of these options is satisfactory due to the low applicability of surgery for patients with poorly localized or multifocal seizures and the limited success of currently available alternative treatment options. In this study, patients with medically refractory focal epilepsy will be treated with intracerebroventricular (ICV) administration of CT-010, a reformulation of valproate, using an implantable drug pump system. This is a randomized, double-blind Phase 2 study evaluating the efficacy and safety of this therapy. Clinical assessments, adverse events (AEs), seizure diaries, concomitant medications, blood samples and cerebrospinal fluid (CSF) will be collected and reviewed at designated time points. Magnetic resonance imaging (MRI) and electroencephalography (EEG) will also be performed. Subjects will have their surgery, dose changes and pharmacokinetics performed in an inpatient setting. Subjects will be enrolled based on Inclusion/Exclusion Criteria and undergo a 6-week baseline period confirming and establishing monthly seizure rate. Following the baseline period subjects will undergo system implant and a 1-month implant recovery period. Following successful implant and recovery subjects will be randomized to either active therapy or placebo for a 3-month blinded evaluation period. At the conclusion of the blinded evaluation period, subjects will roll into an Open Label Extension Period, CLN100P.02. Subjects that were randomized to placebo will receive active therapy during CLN100P.02. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04153175
Study type Interventional
Source Cerebral Therapeutics LLC
Contact
Status Terminated
Phase Phase 2
Start date August 21, 2020
Completion date March 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT02866240 - Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy N/A
Withdrawn NCT04753983 - A Study to Evaluate fMRI of Active DBS Stimulation in Epilepsy N/A
Completed NCT01899898 - Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05493722 - Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy Early Phase 1
Recruiting NCT03062514 - Trial to Evaluate the Safety and Effectiveness of Vagus Nerve Stimulation for Children With Refractory Epilepsy N/A
Recruiting NCT04770337 - Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy N/A
Recruiting NCT05232630 - Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes Phase 4
Completed NCT04545346 - The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy N/A
Not yet recruiting NCT04542629 - Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children Phase 4
Terminated NCT03570489 - Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy: N/A
Completed NCT05031208 - Acute and Long Term Effects of VNS on Memory in Patients With Refractory Epilepsy N/A
Completed NCT01880333 - Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy Phase 2/Phase 3
Completed NCT03676569 - Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy Phase 1
Withdrawn NCT03115489 - Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus Phase 2/Phase 3
Completed NCT02876289 - Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon) N/A
Completed NCT01521754 - Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
Recruiting NCT04684797 - Localization of the Reward Positivity to ACC N/A
Completed NCT05292183 - Modulation of Emotion Perception in Humans Via Amygdala Stimulation N/A
Terminated NCT04398667 - European Non-interventional Study on Refractory Epilepsy With Developmental Delay
Active, not recruiting NCT04218812 - Clinical Utility of Automated Electric Source Imaging in Presurgical Evaluation N/A